REFERENCES
1. Yasui T, Fujita M. Anticoagulation for atrial fibrillation in patients with cancer. Circ J. 2022;86:211-2.
2. Siontis KC, Noseworthy PA, Ruddy KJ. Atrial fibrillation and cancer: where biology and epidemiology intertwine. JACC CardioOncol. 2021;3:233-5.
3. Shaaban A, Scott SS, Greenlee AN, et al. Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms. J Mol Cell Cardiol. 2024;194:118-32.
4. Melloni C, Shrader P, Carver J, et al. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes. 2017;3:192-7.
5. Vinter N, Christesen AMS, Fenger-Grøn M, Tjønneland A, Frost L. Atrial fibrillation and risk of cancer: a danish population-based cohort study. J Am Heart Assoc. 2018;7:e009543.
6. Chen Q, Van Rein N, Van Der Hulle T, et al. Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study. Eur Heart J. 2024;45:2201-13.
7. Müller AD, Sonnenberg A, Wasserman IH. Diseases preceding colon cancer: a case-control study among veterans. Dig Dis Sci. 1994;39:2480-4.
8. Kahr PC, Hammerl S, Huber-Schönauer U, et al. Atrial fibrillation: a new indicator for advanced colorectal neoplasia in screening colonoscopy. J Clin Med. 2019;8:1083.
9. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006-10.
10. Guzzetti S, Costantino G, Vernocchi A, Sada S, Fundarò C. First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation. Intern Emerg Med. 2008;3:227-31.
11. Gonçalves-Teixeira P, Costa T, Fragoso I, et al. Screening, diagnosis and management of atrial fibrillation in cancer patients: current evidence and future perspectives. Arq Bras Cardiol. 2022;119:328-41.
12. Fradley MG, Ellenberg K, Alomar M, et al. Patterns of anticoagulation use in patients with cancer with atrial fibrillation and/or atrial flutter. JACC CardioOncol. 2020;2:747-54.
13. Wang T, Liu X, Zhu Y, et al. Antithrombotic strategy in cancer patients comorbid with acute coronary syndrome and atrial fibrillation. Front Cardiovasc Med. 2023;10:1325488.
14. Brown JD, Goodin AJ, Lip GYH, Adams VR. Risk stratification for bleeding complications in patients with venous thromboembolism: application of the HAS-BLED bleeding score during the first 6 months of anticoagulant treatment. J Am Heart Assoc. 2018;7:e007901.
15. Aziz J, Wang T, Siegal D, et al. Thrombotic and bleeding outcomes following the perioperative interruption of anticoagulation among patients with nonvalvular atrial fibrillation and active cancer. J Thromb Haemost. 2023;21:933-43.
16. Yao X, Gersh BJ, Sangaralingham LR, et al. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation. Am J Cardiol. 2017;120:1549-56.
17. Mosaad M, Elnaem MH, Cheema E, et al. Cancer-associated thrombosis: a clinical scoping review of the risk assessment models across solid tumours and haematological malignancies. Int J Gen Med. 2021;14:3881-97.
18. Grewal K, Wang X, Austin PC, et al. Bleeding and new malignancy diagnoses after anticoagulation for atrial fibrillation: a population-based cohort study. Circulation. 2025;151:773-82.
19. Angeli F, Bergamaschi L, Armillotta M, et al. Impact of newly diagnosed cancer on bleeding events in patients with atrial fibrillation treated with direct oral anticoagulants. Am J Cardiovasc Drugs. 2024;24:813-21.
20. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2014;64:e1-76.
21. Iftimi AA, Rodríguez-Bernal CL, Peiró S, et al. Association of vitamin K and non-vitamin K oral anticoagulant use and cancer incidence in atrial fibrillation patients. Clin Pharmacol Ther. 2021;111:200-8.
22. Camidge R, Reigner B, Cassidy J, et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol. 2005;23:4719-25.
23. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-83.
24. Sherwood MW, Nessel CC, Hellkamp AS, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol. 2015;66:2271-81.
25. Yang P, Zhu D, Xu X, et al. Efficacy and safety of oral anticoagulants in atrial fibrillation patients with cancer—a network meta-analysis. Heart Fail Rev. 2019;25:823-31.
26. Rutherford OW, Jonasson C, Ghanima W, Söderdahl F, Halvorsen S. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2020;6:75-85.
27. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509-24.
28. Naito R, Miyauchi K, Yasuda S, et al. Rivaroxaban monotherapy vs combination therapy with antiplatelets on total thrombotic and bleeding events in atrial fibrillation with stable coronary artery disease: a post hoc secondary analysis of the AFIRE trial. JAMA Cardiol. 2022;7:787.
29. Cho MS, Kang D, Ahn J, et al. Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease. N Engl J Med. 2024;391:2075-86.
30. Patti G, Wang R, Marston XL, et al. Anticoagulant treatment adherence and persistence in german patients with atrial fibrillation. Cardiol Ther. 2023;12:371-91.
31. Spyropoulos A, Al-Badri A, Sherwood M, Douketis J. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost. 2016;14:875-85.
32. Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American college of cardiology clinical expert consensus document task force. J Am Coll Cardiol. 2017;69:871-98.
33. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823-33.
34. Douketis JD, Spyropoulos AC. Perioperative management of patients taking direct oral anticoagulants: a review. JAMA. 2024;332:825-34.
35. Veitch AM, Radaelli F, Alikhan R, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Gut. 2021;70:1611-28.
36. Ullah W, Dimeglio M, Frisch DR, et al. Outcomes and discriminatory accuracy of the CHA2DS2VASc score in atrial fibrillation and cancer. JACC Adv. 2023;2:100609.
37. Seth L, Stabellini N, Doss S, et al. Atrial fibrillation and ischemic stroke in cancer: the latest scientific evidence, current management, and future directions. J Thromb Thrombolysis. 2025;58:1081-94.
38. Ajabnoor AM, Zghebi SS, Parisi R, et al. Performance of CHA2DS2-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer. Eur Heart J Open. 2024;4:oeae053.
39. Raposeiras Roubín S, Abu Assi E, Muñoz Pousa I, et al. Incidence and predictors of bleeding in patients with cancer and atrial fibrillation. Am J Cardiol. 2022;167:139-46.
40. Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study. Oncologist. 2017;22:1222-31.
